Laboratorio Farmaceutico SIT (hereinafter “SIT”) announces the acquisition of MIZOLLEN, a leading H1 long-acting antihistamine.
The product is indicated for the symptomatic treatment of seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and urticaria.
This acquisition will allow SIT to strengthen and expand its product portfolio, significantly increasing its presence in the French market and consolidating its role as a reliable partner in international acquisitions of mature branded pharmaceuticals.
SIT continues its path of innovation and growth, enhancing its offering and presence in international markets to meet the needs of patients and healthcare professionals with reliable, high-quality solutions.
The team at De Berti Jacchia – which advised SIT on all legal aspects of the transaction, overseeing and coordinating the deal structure as a whole – was led by partner Pietro Meda, with the support of partner Claudio Corba Colombo, both members of the M&A department, and assisted by senior associates Benedetta Mazzotti and Francesca Zironi.
Intellectual property matters were handled by partner Andrea Terragni, supported by senior associate Laura Bussoli.
Banking aspects were overseen by partner Giuseppe Cristiano.